Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kesarwani, Meenu ^a   Huber, Erika ^a   Kincaid, Zachary ^a   Evelyn, Chris R ^a   Biesiada, Jacek ^a   Rance, Mark ^b   Thapa, Mahendra B ^b   Shah, Neil P ^c   Meller, Jarek ^a   Zheng, Yi ^a   Azam, Mohammad ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CODON; FEDRATINIB; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; RUXOLITINIB; SULFONAMIDE;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; CODON; CONFORMATION; DRUG RESISTANCE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MULTIDRUG RESISTANCE; MUTATION; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; AMINO ACID SUBSTITUTION; BINDING SITES; CATALYTIC DOMAIN; CODON; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRROLIDINES; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 84942877742     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14538     Document Type: Article

References (56)

1. Daley, G. Q., Van Etten, R. A., Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
2. Druker, B. J. Perspectives on the development of imatinib and the future of cancer research. Nat Med 15, 1149-1152 (2009).
3. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2, 561-566 (1996).
4. Sawyers, C. Targeted cancer therapy. Nature 432, 294-297 (2004).
5. Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
6. Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
7. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352, 1779-1790 (2005).
8. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005).
9. Ihle, J. N., Gilliland, D. G. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17, 8-14 (2007).
10. Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153-166 (2012).
11. LaFave, L. M., Levine, R. L. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends in pharmacological sciences 33, 574-582 (2012).
12. Akada, H. et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115, 3589-3597 (2010).
13. Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584-596 (2010).
14. Zaleskas, V. M. et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 1, e18 (2006).
15. Quintas-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109-3117 (2010).
16. Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-320 (2008).
17. Tyner, J. W. et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115, 5232-5240 (2010).
18. Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721-2730 (2012).
19. Eghtedar, A. et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 119, 4614-4618 (2012).
20. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363, 1117-1127 (2010).
21. Verstovsek, S. et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120, 1202-1209 (2012).
22. Pagliarini, R., Shao, W., Sellers, W. R. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO reports (2015).
23. Weinstein, I. B., Joe, A. Oncogene addiction. Cancer Res 68, 3077-3080; discussion 3080 (2008).
24. Geyer, H. L., Mesa, R. A. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 124, 3529-3537 (2014).
25. Lucet, I. S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 (2006).
26. Bandaranayake, R. M. et al. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 19, 754-759 (2012).
27. Arnold, K., Bordoli, L., Kopp, J., Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
28. Azam, M., Latek, R. R., Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
29. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
30. Funakoshi-Tago, M., Pelletier, S., Moritake, H., Parganas, E., Ihle, J. N. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 28, 1792-1801 (2008).
31. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005).
32. Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., Daley, G. Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15, 1109-1118 (2008).
33. Zhou, Y. J. et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 8, 959-969 (2001).
34. Ungureanu, D. et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18, 971-976.
35. Grosdidier, A., Zoete, V., Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39, W270-277 (2011).
36. Levinson, N. M. et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 4, e144 (2006).
37. Jura, N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42, 9-22 (2011).
38. Azam, M. et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 103, 9244-9249 (2006).
39. Koppikar, P. et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159 (2012).
40. Tong, L. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature structural biology 4, 311-316 (1997).
41. Sanz, A. et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One 6, e18522 (2011).
42. Glickman, M. S., Sawyers, C. L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 148, 1089-1098 (2012).
43. Krause, D. S., Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353, 172-187 (2005).
44. Deshpande, A. et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 26, 708-715 (2012).
45. Marit, M. R. et al. Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One 7, e43437 (2012).
46. Weigert, O. et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. The Journal of experimental medicine 209, 259-273 (2012).
47. Croker, B. A., Kiu, H., Nicholson, S. E. SOCS regulation of the JAK/STAT signalling pathway. Seminars in cell & developmental biology 19, 414-422 (2008).
48. Gumireddy, K. et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102, 1992-1997 (2005).
49. Heine, A. et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122, 1192-1202 (2013).
50. Mullally, A. et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood 121, 3692-3702 (2013).
51. Shi, J. G. et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. Journal of clinical pharmacology 51, 1644-1654 (2011).
52. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
53. Azam, M. et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des 75, 223-227 (2010).
54. O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
55. Chan, W. W. et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19, 556-568.
56. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).